个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Targeting epigenetic modifications in Parkinson's disease therapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Zhang Dan[1] ; Zhang Jifa[1] ; Wang Yuxi[1,2] ; Wang Guan[1] ; Tang Pan[1] ; Liu Yun[1] ; Zhang Yiwen[1,*1] ; Ouyang Liang[1,*1] ;
机构： [1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy and Joint Research Institution of Altitude Health and National Clinical Research Center for Geriatrics，West China Hospital, Sichuan University, Sichuan, Chengdu, China [2]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease‐Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
出处：
DOI： 10.1002/med.21962
ISSN：

关键词： DNA methyltransferase epigenetics histone deacetylases miRNA Parkinson's disease (PD)

摘要：
Parkinson's disease (PD) is a multifactorial disease due to a complex interplay between genetic and epigenetic factors. Recent efforts shed new light on the epigenetic mechanisms involved in regulating pathways related to the development of PD, including DNA methylation, posttranslational modifications of histones, and the presence of microRNA (miRNA or miR). Epigenetic regulators are potential therapeutic targets for neurodegenerative disorders. In the review, we aim to summarize mechanisms of epigenetic regulation in PD, and describe how the DNA methyltransferases, histone deacetylases, and histone acetyltransferases that mediate the key processes of PD are attractive therapeutic targets. We discuss the use of inhibitors and/or activators of these regulators in PD models or patients, and how these small molecule epigenetic modulators elicit neuroprotective effects. Further more, given the importance of miRNAs in PD, their contributions to the underlying mechanisms of PD will be discussed as well, together with miRNA-based therapies.© 2023 Wiley Periodicals LLC.

基金：
National Major Scientific and Technological Special Project for Significant New Drugs Development, Grant/Award Number: 2018ZX09201018‐021; Sichuan Science and Technology Program, Grant/Award Number: 2019YFS0003; National Natural Science Foundation of China, Grant/Award Numbers: 81922064, 81903502; China Postdoctoral Science Foundation, Grant/Award Number: 2020M673268
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 药物化学 1 区 药学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 药物化学 1 区 药学
第一作者：
第一作者机构： [1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy and Joint Research Institution of Altitude Health and National Clinical Research Center for Geriatrics，West China Hospital, Sichuan University, Sichuan, Chengdu, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy and Joint Research Institution of Altitude Health and National Clinical Research Center for Geriatrics，West China Hospital, Sichuan University, Sichuan, Chengdu, China [*1]Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
推荐引用方式(GB/T 7714)：
Zhang Dan,Zhang Jifa,Wang Yuxi,et al.Targeting epigenetic modifications in Parkinson's disease therapy[J].Medicinal research reviews.2023,doi:10.1002/med.21962.
APA：
Zhang Dan,Zhang Jifa,Wang Yuxi,Wang Guan,Tang Pan...&Ouyang Liang.(2023).Targeting epigenetic modifications in Parkinson's disease therapy.Medicinal research reviews,,
MLA：
Zhang Dan,et al."Targeting epigenetic modifications in Parkinson's disease therapy".Medicinal research reviews .(2023)

相关文献

[1]Transcriptome Analysis and Epigenetics Regulation in the Hippocampus and the Prefrontal Cortex of VPA-Induced Rat Model [2]Recent progress in DNA methyltransferase inhibitors as anticancer agents [3]Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. [4]Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. [5]Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O-6-methylguanine DNA-methyltransferase [6]Epigenetics of Triple-negative breast cancer via natural compounds. [7]miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. [8]Identification of prognostic and subtype-specific potential miRNAs in thymoma [9]Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. [10]miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR

资源点击量：46424 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号